First Patient Randomized in the PARADIGM4TB Trial in Europe– Expanding Tuberculosis Research Across Continents

UNITE4TB (https://www.unite4tb.org/) is a global public-private partnership, that brings together leading academic institutions, pharmaceutical companies, and research organizations to accelerate the development of more effective tuberculosis (TB) therapies. Since its launch in 2021, the consortium has built a global network of scientific partnerships and clinical research sites.

Today, we are pleased to announce that, following the successful implementation of the trial in Africa, the study has now expanded to Europe and the first patient has been successfully randomized on 10.02.2025 in the PARADIGM4TB clinical trial in Moldova, marking a significant step in the global effort to develop innovative, effective and shorter TB treatments over the continents.

PARADIGM4TB is a platform clinical trial designed to evaluate innovative TB treatment regimens, aiming to improve outcomes and reduce treatment duration.

Ohanna Kirakosyan from the Research Center Borstel is responsible for coordinating the European trial sites, ensuring the efficient and high-quality implementation of the study across multiple locations in Europe. Dr. Dumitru Chesov, wo works in Borstel and Chisinau is together with Dr. Elena Tudor the principle investigator of the PARADIGM4TB trial at the Moldova site in Chisinau at the Chiril Draganuic Institute. Collins Musia from Borstel is co-leader of the biomarker group in UNITE4TB searching for new tests that can predict responses to novel treatment regimens. Prof. Christoph Lange, Medical Director of the Research Center Borstel, is the clinical lead of the trial.

The expansion of the PARADIGM4TB trial to Europe represents a critical milestone in TB research. As the trial progresses, UNITE4TB remains committed to advancing scientific innovation to combat one of the world’s deadliest infectious diseases. We hope to get more sites to be included in the trial and, of course, we aim to work towards having more European trial sites, thus bringing innovation accessible also in the European region.